Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: CEOs on global tensions; Roche’s new Alzheimer's contender; Sanofi eyes external deals; investors’ reactions to clinical data; and Korean licensing pitfalls
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 3 November 2023, including: CEOs on global tensions; Roche’s new Alzheimer's contender; Sanofi eyes external deals; investors’ reactions to clinical data; and Korean licensing pitfalls
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "A Gloomy Outlook On Macro Trends From Industry CEOs" - Scrip, 1 Nov, 2023.)
(Also see "CTAD 2023: Roche’s Trontinemab Shows Rapid, Deep Amyloid Clearance Lacking From Gantenerumab" - Scrip, 26 Oct, 2023.)
(Also see "Sanofi Eyes External Deals On Top Of Promising Pipeline" - Scrip, 30 Oct, 2023.)
(Also see "Tempest Changes The Atmosphere" - Scrip, 31 Oct, 2023.)
(Also see "How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing" - Scrip, 30 Oct, 2023.)